Clinical Studies and Other Therapeutic Resources
Here’s your one-stop source for viewing and downloading ENTYCE® (capromorelin oral solution) white papers, recent clinical studies and more.
Capromorelin increases food consumption and body weight for 4 consecutive days to healthy adult beagle dogs. The objective of this study was to evaluate the effectiveness of capromorelin oral solution (ENTYCE) by measuring increases in appetite and food consumption.
Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite. The objective of the study was to evaluate the safety of capromorelin, a ghrelin receptor agonist that stimulates appetite and causes increased body weight and the release of growth hormone.
A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. The objective of this study was to evaluate the effectiveness and safety of capromorelin oral solution (ENTYCE), a ghrelin receptor agonist, for the stimulation of appetite in dogs with reduced appetite.
ENTYCE (capromorelin oral solution) technical monograph. This resource provides a therapeutic overview of ENTYCE that includes the mechanism of action, clinical use, safety and efficacy data. It also includes a review of inappetence and how to control appetite in dogs.
Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult beagle dogs. The objective of the study was to determine the effects in dogs of oral capromorelin, a ghrelin receptor agonist, at different doses for 7 days.
Inappetence: Its Many Forms and Clinical Management. This reprint from Clinician’s Forum presents expert views on the clinical and emotional impact of inappetence, the importance of early recognition and approaches to managing the symptom of inappetence.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
Other therapeutics from Aratana
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls cranial cruciate ligament (CCL) post-op pain with one dose for up to 72 hours.
You can be sure that the local relief will help keep your patient is comfortable even after going home.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.